Potential advantages of acute kidney injury management by mesenchymal stem cells

Table 1 Clinical studies on the application of mesenchymal stem cells in acute kidney injury

Study	Phase	Aim	Enrolled patients	Status
NCT00733876	Phase 1	To determine the safety of the administration of allogeneic MSCs at defined doses in patients with high risk of developing AKI after undergoing on-pump cardiac surgery	15	Completed[52]
NCT01275612	Phase 1	To test the feasibility and safety of systemic infusion of donor ex-vivo expanded MSCs to repair kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin	3 (estimated enrollment 9 patients)	Ongoing and recruiting patients
NCT01602328	Phase 2	To evaluate kidney recovery after a single injection of allogeneic bone marrow derived MSCs in patients who experience kidney injury within 48 h of their cardiac surgery	156	Terminated

MSCs: Mesenchymal stem cells; AKI: Acute kidney injury.